Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.

Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...

For valuable insights into Boston Scientific's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our ...

for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...

Co-founded company that makes sacral neuromodulation device to treat patients with overactive bladder conditions.   IN THE ...

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

Boston Scientific (BSX) announced the close of its acquisition of Axonics (AXNX). The purchase price of $71 cash per share represents an ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...